Drug Trial Radar · NCT05211986
Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Sep 13, 2022
Primary completion
Jul 27, 2026
Study completion Jul 27, 2026
Sponsor
- Lead sponsor
- Immunis, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in participants with muscle atrophy related to knee osteoarthritis
Conditions
- Muscle Atrophy
Interventions
IMM01-STEMDrug
IMM01-STEM is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of IMMUNA(IMM01-STEM) treatment in study participants with muscle atrophy related to KOATime frame: Day 0 to Day 28
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Orthopaedic Specialty Institute
Irvine, California
University of California, Irvine - Alpha Stem Cell Clinic
Orange, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.